EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Factors Impacting Continuation of Onabotulinum Toxin Therapy for Idiopathic and Neurogenic Urgency Urinary Incontinence

Faktoren, die die Fortsetzung einer Onabotulinumtoxin-Therapie bei idiopathischer und neurogener Dranginkontinenz beeinflussen

Zhina Sadeghi iD, Emma C Bethel, Stephanie Daignault-Newton iD, Giulia M Ippolito iD, Adriana Rush, Joel Gelman iD, Paholo G Barboglio Romo iD, Anne P Cameron iD, J Quentin Clemens iD, Priyanka Gupta iD, John T Stoffel iD

Neurourology and Urodynamics · 29.10.2026

DOI: 10.1002/nau.70516 ↗

Auf einen Blick

In einer retrospektiven Kohorte setzte etwa 40 % der Patient:innen die BTX-Therapie fort. Eine neurogene Diagnose war mit höherer Therapiepersistenz verbunden.

Fragestellung

Welche demografischen, diagnostischen und sozioökonomischen Faktoren sind mit Fortsetzung oder Abbruch einer Onabotulinumtoxin-Therapie bei erwachsenen Patient:innen mit UUI assoziiert?

Methode

Retrospektive Kohortenstudie an einem tertiären akademischen Zentrum; Identifikation von BTX-Start 2015–2018 und Follow-up bis 2020; Analyse demografischer und sozioökonomischer Faktoren.

Ergebnisse

723 Patient:innen; 40 % erhielten innerhalb von 2 Jahren weitere Injektionen, 60 % nicht. Höherer Affluence Index war mit geringerer Wahrscheinlichkeit des Abbruchs assoziiert (OR 0,90 pro 0,1 Einheit; 95 %-KI 0,82–0,99).

Schlussfolgerung der Autor:innen

Etwa 40 % setzten BTX über die initiale Injektionsperiode hinaus fort. Nach Anpassung war die neurogene Diagnose stark mit Therapiepersistenz assoziiert; sozioökonomische Faktoren waren nicht unabhängig assoziiert.

Kernaussagen

  • Etwa 40 % setzten die BTX-Therapie fort
  • Neurogene Diagnose: höhere Therapiepersistenz
  • Sozioökonomie nach Anpassung nicht unabhängig assoziiert

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Neurourology and Urodynamics, online erschienen am 29.10.2026. Verfasst von Zhina Sadeghi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Division of Reconstructive Urology, University of California, Irvine, California, USA. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, National Institutes of Health.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We investigated demographic, diagnostic, and socioeconomic variables associated with continuation and discontinuation of onabotulinum toxin (BTX) therapy in adult patients treated for idiopathic and neurogenic urgency urinary incontinence (UUI).

Methods

Patients who initiated BTX for UUI between 2015 and 2018 at a tertiary academic referral center were identified from CPT codes and followed through 2020 ( n = 723). The cohort was divided into patients who continued BTX therapy (received ≥1 BTX treatment within 2 years of initial injection) (Group A), and patients who stopped BTX (received no additional BTX for at least 2 years after the last injection) (Group B). Demographic variables were extracted using chart review and administrative data. Socioeconomic differences were estimated using affluence index (AI) and disadvantage index (DI) from their last botox injection, calculated using U.S. census tract indicators. AI factors include household income, professions of household members, and educational background. DI factors include neighborhood proportion of female‐headed households, receiving public assistance or not, household income level, and level of employment. Indexes ranged from 0.0 (least affluent or disadvantaged) to 1.0 (most affluent or advantaged).

Results

The mean cohort age ( n = 723) was 57% and 69% were female. After the initial injection, 40% received additional injections within 2 years (Group A) and 60% did not (Group B). There were no demographic differences between groups. Univariate comparison of affluence and disadvantage indexes revealed Group A affluence was not significantly different (AI = 0.38 vs 0.37, p = 0.2) but was slightly less disadvantaged (DI = 0.072, vs. 0.081; p = 0.036) than Group B. Multivariable analysis including demographic and socioeconomic factors demonstrated that higher affluence index was associated with lower odds of BTX discontinuation (OR = 0.90 per 0.1‐unit increase, 95% CI: 0.82–0.99, p = 0.029), while there was insufficient evidence of an association between disadvantage index and discontinuation (OR = 1.23 per 0.1‐unit increase, 95% CI: 0.99–1.54, p = 0.06). After adding neurogenic versus non‐neurogenic etiology of UUI, the socioeconomic associations were no longer significant. Patients with a non‐neurogenic diagnosis had significantly greater odds of BTX discontinuation than patients with a neurogenic diagnosis (OR = 1.97, 95% CI: 1.35–2.89, p < 0.001).

Conclusion

Approximately 40% of patients continued BTX treatment for UUI beyond the initial injection period. Neurogenic diagnosis was strongly associated with treatment persistence, with non‐neurogenic patients demonstrating greater odds of discontinuation. Socioeconomic factors were not independently associated with discontinuation after adjustment for clinical diagnosis. Clinical Trial Registration This is a retrospective study with IRB approval. This study is not a clinical trial and will not be registered as a clinical trial.

Schlagwörter

Stichwörter der Autor:innen

continuation of onabotulinum toxinneurogenic bladderneurogenic lower urinary tract dysfunctionoveractive bladderurgency urinary incontinence

Autor:innen und Institutionen

  • Department of Urology, Division of Reconstructive Urology, University of California, Irvine, California, USA.
  • Department of Urology, Division of Neurourology and Pelvic Reconstructive Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.

ORCID-Profile: Zhina Sadeghi, Stephanie Daignault-Newton, Giulia M Ippolito, Joel Gelman, Paholo G Barboglio Romo, Anne P Cameron, J Quentin Clemens, Priyanka Gupta, John T Stoffel

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Sadeghi, Z., Bethel, E. C., Daignault-Newton, S., Ippolito, G. M., Rush, A., Gelman, J., Romo, P. G. B., Cameron, A. P., Clemens, J. Q., Gupta, P., & Stoffel, J. T. (2026). Factors Impacting Continuation of Onabotulinum Toxin Therapy for Idiopathic and Neurogenic Urgency Urinary Incontinence. Neurourology and Urodynamics. https://doi.org/10.1002/nau.70516

Vancouver

Sadeghi Z, Bethel EC, Daignault-Newton S, Ippolito GM, Rush A, Gelman J, et al. Factors Impacting Continuation of Onabotulinum Toxin Therapy for Idiopathic and Neurogenic Urgency Urinary Incontinence. Neurourology and Urodynamics. 2026. doi:10.1002/nau.70516

BibTeX
@article{Sadeghi2026,
  author = {Sadeghi, Zhina and Bethel, Emma C and Daignault-Newton, Stephanie and Ippolito, Giulia M and Rush, Adriana and Gelman, Joel and Romo, Paholo G Barboglio and Cameron, Anne P and Clemens, J Quentin and Gupta, Priyanka and Stoffel, John T},
  title = {Factors Impacting Continuation of Onabotulinum Toxin Therapy for Idiopathic and Neurogenic Urgency Urinary Incontinence},
  journal = {Neurourology and Urodynamics},
  year = {2026},
  doi = {10.1002/nau.70516}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche